Article Information
History
- July 6, 2020.
Article Versions
- Version 1 (May 20, 2020 - 08:10).
- You are currently viewing Version 2 of this article (July 6, 2020 - 13:00).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Lucas M. Kimmig, MD1,2,*,
- David Wu, MD, PhD1,2,*,
- Matthew Gold, MD1,
- Natasha N Pettit, PharmD1,3,
- David Pitrak, MD1,3,
- Jeffery Mueller, DO4,
- Aliya N. Husain, MD4,
- Ece A. Mutlu, MD, MS, MBA5 and
- Gökhan M. Mutlu, MD1,2,†
- 1Department of Medicine, University of Chicago, Chicago, Illinois
- 2Section of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois
- 3Section of Infectious Diseases, University of Chicago, Chicago, Illinois
- 4Department of Pathology, University of Chicago, Chicago, Illinois
- 5Section of Gastroenterology and Hepatology, Rush University, Chicago, Illinois
- ↵†Corresponding author: Gökhan M. Mutlu, MD, Section of Pulmonary and Critical Care Medicine, University of Chicago, 5841 S Maryland Ave, MC6026, Chicago, IL 60637, Phone: 773-703-1002, Fax: 773-702-6500, Email: gmutlu{at}uchicago.edu
↵* Equal contribution
Posted July 06, 2020.
IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections
